Abstract
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non – small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and genes mutations involved in lung tumors. Additionally, recent proteomic and microRNAs approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.
Keywords: Lung cancer, oncosuppressors, oncogenes, epigenetics of lung cancer, diagnostic tools for lung cancer, cancer, epigenetics, diagnostic, NSCLC, SCLC, KRAS, ERBB2, EGFR, MET, NKX2-1, PIK3CA, SRC, RB1, XRCC1, DAPK1, hTERT, CT, PET, TBNA, EBUS, ERCC1, proteins, miRNAs
Current Genomics
Title: Lung Cancer: Are we up to the Challenge?
Volume: 11 Issue: 7
Author(s): Luca Esposito, Daniele Conti, Ramyasri Ailavajhala, Nansie Khalil and Antonio Giordano
Affiliation:
Keywords: Lung cancer, oncosuppressors, oncogenes, epigenetics of lung cancer, diagnostic tools for lung cancer, cancer, epigenetics, diagnostic, NSCLC, SCLC, KRAS, ERBB2, EGFR, MET, NKX2-1, PIK3CA, SRC, RB1, XRCC1, DAPK1, hTERT, CT, PET, TBNA, EBUS, ERCC1, proteins, miRNAs
Abstract: Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non – small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and genes mutations involved in lung tumors. Additionally, recent proteomic and microRNAs approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.
Export Options
About this article
Cite this article as:
Esposito Luca, Conti Daniele, Ailavajhala Ramyasri, Khalil Nansie and Giordano Antonio, Lung Cancer: Are we up to the Challenge?, Current Genomics 2010; 11 (7) . https://dx.doi.org/10.2174/138920210793175903
DOI https://dx.doi.org/10.2174/138920210793175903 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets MicroRNAs as Cancer Biomarkers
MicroRNA Regulation of Arylamine N-Acetyltransferases
Current Drug Metabolism Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC
Current Pharmaceutical Design Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Current Cancer Drug Targets Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Anti-Cancer Agents in Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3- Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4- Benzotriazine-1-Oxide Moiety
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
Current Medicinal Chemistry New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Identifying Candidates for Breast Cancer using Interactions of Chemicals and Proteins
Combinatorial Chemistry & High Throughput Screening GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry